NorthWest Biotherapeutics Inc (NWBO)

[User-840664]

Stop calling people names and educate yourself.

Although the DCVax-L vaccine can trigger the patient’s immune response, specifically T cells, it remains a therapy that has to be accompanied by additional therapeutic agents and has thus found minor success as monotherapy.

(TMZ) into the standard treatment has increased the overall survival rate of glioblastoma patients. Since then, significant advances have been made in understanding the benefits and limitations of TMZ. Among the latter, the unspecific toxicity of TMZ, poor solubility, and hydrolyzation are intrinsic characteristics, whereas the presence of the blood-brain barrier and some tumor properties, such as molecular and cellular heterogeneity and therapy resistance, have limited the therapeutic effects of TMZ in treating glioblastoma.